{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:37:23Z","timestamp":1785551843241,"version":"3.56.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00701-021-04953-6","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:02:26Z","timestamp":1628398946000},"page":"3131-3142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section"],"prefix":"10.1007","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7232-319X","authenticated-orcid":false,"given":"Sam","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Messerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Frederick","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torstein R.","family":"Meling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Paraskevopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W. S.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoya","family":"Zazpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moncef","family":"Berhouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engelbert","family":"Knosp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Jacquesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,8]]},"reference":[{"issue":"4","key":"4953_CR1","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/ERC-17-0004","volume":"24","author":"SL Asa","year":"2017","unstructured":"Asa SL, Casar-Borota O, Chanson P et al (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24(4):C5\u2013C8","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"4953_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1586\/17446651.2016.1153422","volume":"11","author":"SL Asa","year":"2016","unstructured":"Asa SL, Ezzat S (2016) Aggressive pituitary tumors or localized pituitary carcinomas: defining pituitary tumors. Expert Rev Endocrinol Metab 11(2):149\u2013162","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"4953_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0300-595X(83)80056-5","volume":"12","author":"SL Asa","year":"1983","unstructured":"Asa SL, Kovacs K (1983) Histological classification of pituitary disease. Clin Endocrinol Metab 12(3):567\u2013596","journal-title":"Clin Endocrinol Metab"},{"issue":"2","key":"4953_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1530\/EJE-18-0749","volume":"180","author":"S Asioli","year":"2019","unstructured":"Asioli S, Righi A, Iommi M et al (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180(2):127\u2013134","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"4953_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-015-0675-0","volume":"19","author":"X Bao","year":"2016","unstructured":"Bao X, Deng K, Liu X, Feng M, Chen CC, Lian W, Xing B, Yao Y, Wang R (2016) Extended transsphenoidal approach for pituitary adenomas invading the cavernous sinus using multiple complementary techniques. Pituitary 19(1):1\u201310","journal-title":"Pituitary"},{"issue":"4","key":"4953_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schr\u00f8der HD, Andersen M et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689\u20131698","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4953_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12020-018-1751-9","volume":"62","author":"D Bengtsson","year":"2018","unstructured":"Bengtsson D, Schr\u00f8der HD, Berinder K et al (2018) Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine 62(3):737\u2013739","journal-title":"Endocrine"},{"issue":"10","key":"4953_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1055\/s-0030-1253419","volume":"118","author":"H Bode","year":"2010","unstructured":"Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes H-P, Thom\u00e9 C (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Amp Diabetes 118(10):760\u2013763","journal-title":"Exp Clin Endocrinol Amp Diabetes"},{"issue":"1","key":"4953_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1365-2265.2003.01674.x","volume":"58","author":"KJ Bradley","year":"2003","unstructured":"Bradley KJ, Wass JAH, Turner HE (2003) Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently: Natural history of ACTH immunopositive NFAs. Clin Endocrinol (Oxf) 58(1):59\u201364","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4953_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/587893","volume":"2015","author":"OD Bruno","year":"2015","unstructured":"Bruno OD, Ju\u00e1rez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C, G\u00f3mez RM (2015) Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from Argentina. Int J Endocrinol 2015:1\u20138","journal-title":"Int J Endocrinol"},{"issue":"11","key":"4953_CR11","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MBS (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O 6 -methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280\u2013E290","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4953_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy \u2014 immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195\u2013207","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"4953_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrendo.2010.4","volume":"6","author":"F Castinetti","year":"2010","unstructured":"Castinetti F, R\u00e9gis J, Dufour H, Brue T (2010) Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 6(4):214\u2013223","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"4953_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11060-014-1702-0","volume":"122","author":"F Ceccato","year":"2015","unstructured":"Ceccato F, Lombardi G, Manara R et al (2015) Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. J Neurooncol 122(1):189\u2013196","journal-title":"J Neurooncol"},{"issue":"1","key":"4953_CR15","doi-asserted-by":"publisher","first-page":"D1","DOI":"10.1530\/EJE-19-0058","volume":"181","author":"P Chanson","year":"2019","unstructured":"Chanson P, Dormoy A, Dekkers OM (2019) Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol 181(1):D1\u2013D13","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"4953_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000375448","volume":"101","author":"S Chiloiro","year":"2015","unstructured":"Chiloiro S, Doglietto F, Trapasso B et al (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143\u2013150","journal-title":"Neuroendocrinology"},{"key":"4953_CR17","doi-asserted-by":"crossref","unstructured":"Cooper O, Bonert V, Rudnick J, Pressman B, Melmed S (2019) SUN-442 EGFR\/ErbB2 targeted therapy for aggressive prolactinomas. J Endocr Soc 3(Supplement_1):SUN-442","DOI":"10.1210\/js.2019-SUN-442"},{"issue":"4","key":"4953_CR18","first-page":"180","volume":"44","author":"H Cushing","year":"1969","unstructured":"Cushing H (1969) The basophil adenomas of the pituitary body. Ann R Coll Surg Engl 44(4):180\u2013181","journal-title":"Ann R Coll Surg Engl"},{"key":"4953_CR19","doi-asserted-by":"crossref","unstructured":"Dai C, Liang S, Sun B, Kang J (2020) The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol 11:608422","DOI":"10.3389\/fendo.2020.608422"},{"key":"4953_CR20","doi-asserted-by":"crossref","unstructured":"Del Basso De Caro M, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G, Cappabianca P (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40(1):105\u2013114","DOI":"10.1007\/s10143-016-0740-9"},{"key":"4953_CR21","volume-title":"Pathology and genetics of tumours of endocrine organs","year":"2004","unstructured":"DeLellis RA (ed) (2004) Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon"},{"issue":"4","key":"4953_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2217\/cns-2016-0011","volume":"5","author":"LE Donovan","year":"2016","unstructured":"Donovan LE, Arnal AV, Wang S-H, Odia Y (2016) Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. CNS Oncol 5(4):203\u2013209","journal-title":"CNS Oncol"},{"issue":"3","key":"4953_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/jpm10030088","volume":"10","author":"C Duhamel","year":"2020","unstructured":"Duhamel C, Ilie MD, Salle H, Nassouri AS, Gaillard S, Deluche E, Assaker R, Mortier L, Cortet C, Raverot G (2020) Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature. J Pers Med 10(3):88","journal-title":"J Pers Med"},{"issue":"11","key":"4953_CR24","doi-asserted-by":"publisher","first-page":"R559","DOI":"10.1530\/ERC-18-0228","volume":"25","author":"D Dworakowska","year":"2018","unstructured":"Dworakowska D, Grossman AB (2018) Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer 25(11):R559\u2013R575","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"4953_CR25","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1210\/clinem\/dgz211","volume":"105","author":"U Elbelt","year":"2020","unstructured":"Elbelt U, Schlaffer SM, Buchfelder M et al (2020) Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas\u2014a German survey. J Clin Endocrinol Metab 105(3):e660\u2013e675","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4953_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4193\/Rhino14.309","volume":"53","author":"F Ferreli","year":"2015","unstructured":"Ferreli F, Turri-Zanoni M, Canevari FR, Battaglia P, Bignami M, Castelnuovo P, Locatelli D (2015) Endoscopic endonasal management of non-functioning pituitary adenomas with cavernous sinus invasion: a 10- year experience. Rhinol J 53(4):308\u2013316","journal-title":"Rhinol J"},{"key":"4953_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01956","author":"A Fountas","year":"2018","unstructured":"Fountas A, Lavrentaki A, Subramanian A, Toulis KA, Nirantharakumar K, Karavitaki N (2018) Recurrence in silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2018-01956","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4953_CR28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1530\/EC-19-0065","volume":"8","author":"G Giuffrida","year":"2019","unstructured":"Giuffrida G, Ferra\u00f9 F, Laudicella R et al (2019) Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocr Connect 8(5):528\u2013535","journal-title":"Endocr Connect"},{"issue":"3","key":"4953_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00701-013-1959-7","volume":"156","author":"H Halvorsen","year":"2014","unstructured":"Halvorsen H, Ramm-Pettersen J, Josefsen R, R\u00f8nning P, Reinlie S, Meling T, Berg-Johnsen J, Bollerslev J, Helseth E (2014) Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochir (Wien) 156(3):441\u2013449","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"4953_CR30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130\u20131136","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"4953_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","volume":"22","author":"KKY Ho","year":"2019","unstructured":"Ho KKY, Fleseriu M, Wass J et al (2019) A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary 22(6):569\u2013573","journal-title":"Pituitary"},{"issue":"3","key":"4953_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ecl.2020.05.008","volume":"49","author":"MD Ilie","year":"2020","unstructured":"Ilie MD, Jouanneau E, Raverot G (2020) Aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin North Am 49(3):505\u2013515","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"4953_CR33","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1210\/js.2019-00130","volume":"3","author":"BS Imber","year":"2019","unstructured":"Imber BS, Lin AL, Zhang Z et al (2019) Comparison of radiographic approaches to assess treatment response in pituitary adenomas: is RECIST or RANO good enough? J Endocr Soc 3(9):1693\u20131706","journal-title":"J Endocr Soc"},{"issue":"3","key":"4953_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/nop\/npv059","volume":"3","author":"Y Ji","year":"2016","unstructured":"Ji Y, Vogel RI, Lou E (2016) Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. Neuro-Oncol Pract 3(3):188\u2013195","journal-title":"Neuro-Oncol Pract"},{"issue":"1","key":"4953_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","volume":"15","author":"E Jouanneau","year":"2012","unstructured":"Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G (2012) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15(1):37\u201343","journal-title":"Pituitary"},{"issue":"8","key":"4953_CR36","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1590\/S0004-27302007000800017","volume":"51","author":"N Karavitaki","year":"2007","unstructured":"Karavitaki N, Ansorge O, Wass JAH (2007) Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51(8):1314\u20131318","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"1","key":"4953_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.wneu.2015.02.024","volume":"84","author":"A Karppinen","year":"2015","unstructured":"Karppinen A, Kivipelto L, Vehkavaara S, Ritvonen E, Tikkanen E, Kivisaari R, Hernesniemi J, Set\u00e4l\u00e4 K, Schalin-J\u00e4ntti C, Niemel\u00e4 M (2015) Transition from microscopic to endoscopic transsphenoidal surgery for nonfunctional pituitary adenomas. World Neurosurg 84(1):48\u201357","journal-title":"World Neurosurg"},{"issue":"4","key":"4953_CR38","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610\u2013618","journal-title":"Neurosurgery"},{"issue":"1","key":"4953_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/eci.12010","volume":"43","author":"GL Kov\u00e1cs","year":"2013","unstructured":"Kov\u00e1cs GL, G\u00f3th M, Rotondo F et al (2013) ACTH-secreting Crooke cell carcinoma of the pituitary: Crooke cell carcinoma of the pituitary. Eur J Clin Invest 43(1):20\u201326","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"4953_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","volume":"40","author":"DJ Kwekkeboom","year":"2011","unstructured":"Kwekkeboom DJ, de Herder WW, Krenning EP (2011) Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):173\u2013185","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"4953_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/cancers12020308","volume":"12","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim H-W, McCormack AI (2020) Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature\u2014\u201care we there yet?\u201d Cancers 12(2):308","journal-title":"Cancers"},{"issue":"2","key":"4953_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11102-017-0858-y","volume":"21","author":"F Langlois","year":"2018","unstructured":"Langlois F, Woltjer R, Cetas JS, Fleseriu M (2018) Silent somatotroph pituitary adenomas: an update. Pituitary 21(2):194\u2013202","journal-title":"Pituitary"},{"issue":"1","key":"4953_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"6","key":"4953_CR44","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle H, Cortet C, Castinetti F et al (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176(6):769\u2013777","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"4953_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1530\/EJE-17-0965","volume":"178","author":"J Lelotte","year":"2018","unstructured":"Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D (2018) Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Eur J Endocrinol 178(3):237\u2013246","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"4953_CR46","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V et al (2018) Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103(10):3925\u20133930","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"4953_CR47","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/neuonc\/now059","volume":"18","author":"AL Lin","year":"2016","unstructured":"Lin AL, Sum MW, DeAngelis LM (2016) Is there a role for early chemotherapy in the management of pituitary adenomas? Neuro-Oncol 18(10):1350\u20131356","journal-title":"Neuro-Oncol"},{"issue":"3","key":"4953_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","volume":"126","author":"M Losa","year":"2016","unstructured":"Losa M, Bogazzi F, Cannavo S et al (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126(3):519\u2013525","journal-title":"J Neurooncol"},{"issue":"6","key":"4953_CR49","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","volume":"17","author":"J Maclean","year":"2014","unstructured":"Maclean J, Aldridge M, Bomanji J, Short S, Fersht N (2014) Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation. Pituitary 17(6):530\u2013538","journal-title":"Pituitary"},{"issue":"3","key":"4953_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276","journal-title":"Eur J Endocrinol"},{"issue":"47","key":"4953_CR51","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF et al (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7(47):76565\u201376576","journal-title":"Oncotarget"},{"issue":"2","key":"4953_CR52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3171\/jns.2002.96.2.0195","volume":"96","author":"BP Meij","year":"2002","unstructured":"Meij BP, Lopes M-BS, Ellegala DB, Alden TD, Laws ER (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2):195\u2013208","journal-title":"J Neurosurg"},{"issue":"4","key":"4953_CR53","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/2011.1.FOCUS10308","volume":"30","author":"M Messerer","year":"2011","unstructured":"Messerer M, De battista JC, Raverot G, Kassis S, Dubourg J, Lapras V, Trouillas J, Perrin G, Jouanneau E, (2011) Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal: personal experience and review of the literature. Neurosurg Focus 30(4):E11","journal-title":"Neurosurg Focus"},{"issue":"2","key":"4953_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/modpathol.2015.151","volume":"29","author":"O Mete","year":"2016","unstructured":"Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29(2):131\u2013142","journal-title":"Mod Pathol"},{"issue":"3","key":"4953_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228\u2013243","journal-title":"Endocr Pathol"},{"issue":"1","key":"4953_CR56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","volume":"3","author":"CP Miermeister","year":"2015","unstructured":"Miermeister CP, Petersenn S, Buchfelder M et al (2015) Histological criteria for atypical pituitary adenomas \u2013 data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3(1):50","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"4953_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11102-018-0868-4","volume":"21","author":"G Minniti","year":"2018","unstructured":"Minniti G, Flickinger J, Tolu B, Paolini S (2018) Management of nonfunctioning pituitary tumors: radiotherapy. Pituitary 21(2):154\u2013161","journal-title":"Pituitary"},{"issue":"2","key":"4953_CR58","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1210\/jc.2004-1152","volume":"90","author":"G Minniti","year":"2005","unstructured":"Minniti G, Traish D, Ashley S, Gonsalves A, Brada M (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90(2):800\u2013804","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4953_CR59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","volume":"19","author":"A Obari","year":"2008","unstructured":"Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82\u201391","journal-title":"Endocr Pathol"},{"issue":"3","key":"4953_CR60","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3171\/2014.5.JNS132817","volume":"121","author":"EH Oldfield","year":"2014","unstructured":"Oldfield EH (2014) Editorial: Management of invasion by pituitary adenomas. J Neurosurg 121(3):501\u2013504","journal-title":"J Neurosurg"},{"key":"4953_CR61","doi-asserted-by":"crossref","unstructured":"On behalf of The Pituitary Society, Expert Group on Pituitary Tumors, Casanueva FF, Barkan AL, et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement. Pituitary 20(5):489\u2013498","DOI":"10.1007\/s11102-017-0838-2"},{"issue":"1","key":"4953_CR62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12020-016-0940-7","volume":"53","author":"KA \u00d8ystese","year":"2016","unstructured":"\u00d8ystese KA, Evang JA, Bollerslev J (2016) Non-functioning pituitary adenomas: growth and aggressiveness. Endocrine 53(1):28\u201334","journal-title":"Endocrine"},{"issue":"4","key":"4953_CR63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-013-0502-4","volume":"17","author":"A Paluzzi","year":"2014","unstructured":"Paluzzi A, Fernandez-Miranda JC, Tonya Stefko S, Challinor S, Snyderman CH, Gardner PA (2014) Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary 17(4):307\u2013319","journal-title":"Pituitary"},{"issue":"12","key":"4953_CR64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1055\/a-1060-1883","volume":"51","author":"S Petersenn","year":"2019","unstructured":"Petersenn S (2019) Management of aggressive pituitary tumors \u2013 a 2019 update. Horm Metab Res 51(12):755\u2013764","journal-title":"Horm Metab Res"},{"key":"4953_CR65","doi-asserted-by":"crossref","unstructured":"Principe M, Chanal M, Ilie MD, Ziverec A, Vasiljevic A, Jouanneau E, Hennino A, Raverot G, Bertolino P (2020) Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion. J Clin Endocrinol Metab 105(11):dgaa520","DOI":"10.1210\/clinem\/dgaa520"},{"issue":"4","key":"4953_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/foc.2004.16.4.8","volume":"16","author":"BT Ragel","year":"2004","unstructured":"Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):1\u20139","journal-title":"Neurosurg Focus"},{"key":"4953_CR67","doi-asserted-by":"crossref","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, __ (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013G24","DOI":"10.1530\/EJE-17-0796"},{"issue":"9","key":"4953_CR68","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1210\/jc.2017-00773","volume":"102","author":"G Raverot","year":"2017","unstructured":"Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102(9):3368\u20133374","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"4953_CR69","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F et al (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592\u20134599","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4953_CR70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","volume":"156","author":"W Saeger","year":"2007","unstructured":"Saeger W, L\u00fcdecke DK, Buchfelder M, Fahlbusch R, Quabbe H-J, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203\u2013216","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"4953_CR71","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3171\/jns.1986.65.6.0733","volume":"65","author":"BW Scheithauer","year":"1986","unstructured":"Scheithauer BW, Kovacs KT, Laws ER, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65(6):733\u2013744","journal-title":"J Neurosurg"},{"issue":"2","key":"4953_CR72","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3171\/2013.3.JNS12766","volume":"119","author":"JP Sheehan","year":"2013","unstructured":"Sheehan JP, Starke RM, Mathieu D et al (2013) Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study: Clinical article. J Neurosurg 119(2):446\u2013456","journal-title":"J Neurosurg"},{"issue":"1","key":"4953_CR73","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"The members of HYPOPRONOS, Trouilla","year":"2013","unstructured":"The members of HYPOPRONOS, Trouillas J, Roy P, et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case\u2013control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (Berl) 126(1):123\u2013135","journal-title":"Acta Neuropathol (Berl)"},{"key":"4953_CR74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","volume":"41","author":"W Touma","year":"2017","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E (2017) Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci 41:75\u201377","journal-title":"J Clin Neurosci"},{"issue":"6","key":"4953_CR75","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1530\/EJE-18-0250","volume":"178","author":"J Trouillas","year":"2018","unstructured":"Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G (2018) Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol 178(6):C7\u2013C9","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"4953_CR76","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000499382","volume":"109","author":"J Trouillas","year":"2019","unstructured":"Trouillas J, Delgrange E, Wierinckx A, Vasiljevic A, Jouanneau E, Burman P, Raverot G (2019) Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours. Neuroendocrinology 109(1):70\u201376","journal-title":"Neuroendocrinology"},{"issue":"2","key":"4953_CR77","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers12020514","volume":"12","author":"J Trouillas","year":"2020","unstructured":"Trouillas J, Jaffrain-Rea M-L, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers 12(2):514","journal-title":"Cancers"},{"key":"4953_CR78","doi-asserted-by":"crossref","unstructured":"Ugga L, Cuocolo R, Solari D, Guadagno E, D\u2019Amico A, Somma T, Cappabianca P, del Basso de Caro ML, Cavallo LM, Brunetti A (2019) Prediction of high proliferative index in pituitary macroadenomas using MRI-based radiomics and machine learning. Neuroradiology 61(12):1365\u20131373","DOI":"10.1007\/s00234-019-02266-1"},{"issue":"3","key":"4953_CR79","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jc.2014-3697","volume":"100","author":"NC van Varsseveld","year":"2015","unstructured":"van Varsseveld NC, van Bunderen CC, Ubachs DHH, Franken AAM, Koppeschaar HPF, van der Lely AJ, Drent ML (2015) Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults. J Clin Endocrinol Metab 100(3):1104\u20131112","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4953_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","volume":"125","author":"J Walig\u00f3rska-Stachura","year":"2016","unstructured":"Walig\u00f3rska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczy\u0144ska M, Baszko-B\u0142aszyk D, Blanco-Gangoo AR, Rucha\u0142a M (2016) Growth hormone\u2013secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report. J Neurosurg 125(2):346\u2013349","journal-title":"J Neurosurg"},{"key":"4953_CR81","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","volume":"124","author":"Y Wang","year":"2019","unstructured":"Wang Y, He Q, Meng X, Zhou S, Zhu Y, Xu J, Tao R (2019) Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review. World Neurosurg 124:319\u2013322","journal-title":"World Neurosurg"},{"key":"4953_CR82","unstructured":"Weltgesundheitsorganisation, Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J, International Agency for Research on Cancer (eds) (2017) WHO classification of tumours of endocrine organs, 4th edition. International Agency for Research on Cancer, Lyon"},{"issue":"3","key":"4953_CR83","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3171\/2015.4.JNS15102","volume":"124","author":"HA Zaidi","year":"2016","unstructured":"Zaidi HA, Awad A-W, Bohl MA, Chapple K, Knecht L, Jahnke H, White WL, Little AS (2016) Comparison of outcomes between a less experienced surgeon using a fully endoscopic technique and a very experienced surgeon using a microscopic transsphenoidal technique for pituitary adenoma. J Neurosurg 124(3):596\u2013604","journal-title":"J Neurosurg"},{"issue":"6","key":"4953_CR84","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang D, Way JS, Zhang X, Sergey M, Bergsneider M, Wang MB, Yong WH, Heaney AP (2019) Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104(6):1929\u20131936","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4953_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0360-3016(95)00071-6","volume":"33","author":"D Zierhut","year":"1995","unstructured":"Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M (1995) External radiotherapy of pituitary adenomas. Int J Radiat Oncol 33(2):307\u2013314","journal-title":"Int J Radiat Oncol"},{"issue":"4","key":"4953_CR86","first-page":"485","volume":"60","author":"M Zoli","year":"2016","unstructured":"Zoli M, Milanese L, Bonfatti R, Sturiale C, Pasquini E, Frank G, Mazzatenta D (2016) Cavernous sinus invasion by pituitary adenomas: role of endoscopic endonasal surgery. J Neurosurg Sci 60(4):485\u2013494","journal-title":"J Neurosurg Sci"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-021-04953-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-021-04953-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-021-04953-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T19:37:43Z","timestamp":1634413063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-021-04953-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,8]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4953"],"URL":"https:\/\/doi.org\/10.1007\/s00701-021-04953-6","relation":{},"ISSN":["0001-6268","0942-0940"],"issn-type":[{"value":"0001-6268","type":"print"},{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,8]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not involve humans, and no informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}